Our study bridges the gap between clinical observations and epigenetic studies of CRC patients with KRAS and BRAF mutations in stage I CRC through a metabolic aging clock, illustrating a spectrum of malignancy with metabolic aging deviations in this stage. Here, KRAS is linked to colorectal carcinoma.